View map

Dr. John Mascarenhas, MD


New York, NY

About Dr. John Mascarenhas

Mount Sinai Oncology will work with patients on a case by case basis to review insurance coverage. Patients can expect a call from the office after booking to discuss these details. The practice will try to accommodate the time selected however the appointment date and time may need to adjusted to better suit the specific patient case. Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based novel therapies for patients with MPNs and AML. Dr. Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML. Additionally, he holds multiple administrative roles at Mount Sinai including Chair of the Leukemia Disease Management Team, Co-Chair of the Hematologic Malignancy Disease Focus Group, and full member of the Tisch Cancer Institute Protocol and Review Monitoring Committee.

In-network insurances

  • 1199SEIU
  • Aetna
  • Aetna Better Health


  • Oncologist

Practice names

Hospital affiliations

  • The Mount Sinai Hospital

Board certifications

  • Hematology (Internal Medicine)
  • Medical Oncology (Internal Medicine)

Education and training

  • Medical School - New York Medical College, Doctor of Medicine
  • Rhode Island Hospital, Residency in Internal Medicine
  • The Mount Sinai Hospital, Fellowship in Hematology

Awards and publications

  • Richard E. Rosenfeld Faculty Achievement Award in 2010
  • Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leukemia research 2017 Sep; 60.
  • Choi DC, Tremblay D, Iancu-Rubin C, Mascarenhas J. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. Annals of hematology 2017 Jun; 96(6).
  • Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, Goldberg JD, Hoffman R. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leukemia research 2017 Feb; 53.
  • Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica 2017 02; 102(2).

Languages spoken

  • English
  • Spanish

Provider's gender


NPI number


Dr. John Mascarenhas's office location

Mount Sinai Cancer

The Ruttenberg Treatment Center

1470 Madison Ave

New York, NY 10029

ZocdocOncologistDr. John Mascarenhas, MD